Provided by Tiger Fintech (Singapore) Pte. Ltd.

Hoth Therapeutics

1.47
+0.140010.53%
Pre-market: 1.43-0.0400-2.72%06:34 EDT
Volume:2.16M
Turnover:3.12M
Market Cap:19.49M
PE:-1.47
High:1.52
Open:1.33
Low:1.33
Close:1.33
52wk High:3.80
52wk Low:0.6506
Shares:13.26M
Float Shares:13.19M
Volume Ratio:0.42
T/O Rate:16.34%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.9971
EPS(LYR):-1.2844
ROE:-104.87%
ROA:-62.11%
PB:2.00
PE(LYR):-1.14

Loading ...

Hoth Therapeutics Inc. Adopts Lantern Pharma's PredictBBB.ai Platform to Enhance Drug Development Precision and Speed

Reuters
·
Sep 04

EXCLUSIVE: Hoth Therapeutics' Antisense Therapy Demonstrates Efficacy Against KIT-Driven Cancers

Benzinga_recent_news
·
Sep 02

Hoth Therapeutics Inc. Reaffirms Leadership with New Employment Agreement for CEO Robb Knie

Reuters
·
Aug 23

Hoth Therapeutics Is Maintained at Buy by D. Boral Capital

Dow Jones
·
Aug 18

Hoth Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary

Reuters
·
Aug 13

Hoth Therapeutics Inc expected to post a loss of 14 cents a share - Earnings Preview

Reuters
·
Aug 06

Hoth Therapeutics Inc. Conducted Annual Shareholder Meeting

Reuters
·
Aug 06

Hoth Therapeutics Expands Phase II Clinical Trial for HT-001 Across Europe in Collaboration with ICON

Reuters
·
Jul 29

Hoth Therapeutics Announces Engagement With ICON and Expansion of Phase Ii Clinical Trial for Ht-001 in Europe

THOMSON REUTERS
·
Jul 29

Hoth Therapeutics Inc - to Extend Phase Ii Trial of Ht-001 in EU

THOMSON REUTERS
·
Jul 29

Hoth Therapeutics Launches Groundbreaking Clinical Study to Compare GDNF and Semaglutide for Obesity and Fatty Liver Treatment

Reuters
·
Jul 22

Hoth Therapeutics Is Maintained at Buy by D. Boral Capital

Dow Jones
·
Jun 26

Silo Pharma, Hoth Therapeutics to Launch Joint Venture for Obesity Treatment

MT Newswires Live
·
Jun 25

BRIEF-Silo Pharma announces Formation Of Joint Venture With Hoth Therapeutics

Reuters
·
Jun 25

BRIEF-Hoth Therapeutics Says 100% Of Patients Achieved Primary Endpoint In HT-001 Phase 2A Trial

Reuters
·
Jun 24